Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.

Clin Cancer Res · 2024 · PMC11443247 · PMID 39058425

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

Final overall survival (OS) results from LOTUS showed a numerical trend favoring ipatasertib-containing therapy in both the intent-to-treat (ITT) and the biomarker-selected populations, with median OS exceeding 2 years ( 11 ).

also in 426 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.